Adaptimmune Therapeutics plc

Equities

ADAP

US00653A1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 17/07/2024 am IST			5-day change	1st Jan Change
1.27 ^USD	+2.01%		+5.83%	+60.15%

15/07	European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading	MT
11/07	European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading	MT

Paul Stead Joins Adaptimmune Therapeutics as Vice President of Business Development

January 04, 2018 at 06:30 pm IST

Adaptimmune Therapeutics plc announced that Paul Stead, B. Pharm, PhD, MBA, MR PharmS has joined the Company as Vice President of Business Development. Paul joins Adaptimmune, most recently, from Inovio Pharmaceuticals Inc.

Latest news about Adaptimmune Therapeutics plc

European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading	15/07	MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading	11/07	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	09/07	MT
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading	08/07	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading	05/07	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	03/07	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	02/07	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	01/07	MT
ADRs End Flat; Alarum Technologies Climbs 26%	28/06	DJ
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	27/06	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	26/06	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading	18/06	MT
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading	14/06	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	07/06	MT
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	05/06	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	04/06	MT
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading	03/06	MT
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower	31/05	MT
Transcript : Adaptimmune Therapeutics plc - Special Call	31/05
Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment	31/05	MT
Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug	31/05	MT
Galapagos and Adaptimmune Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-Cell Therapy Candidate, uza-cel	31/05	CI
Scotiabank Starts Adaptimmune Therapeutics With Sector Outperform Rating	30/05	MT
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading	20/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	17/05	MT

Chart Adaptimmune Therapeutics plc

Duration

Period

More charts

Company Profile

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Companyâs most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Adaptimmune Therapeutics plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.27 USD

Average target price

2.519 USD

Spread / Average Target

+98.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADAPTIMMUNE THERAPEUTICS PLC	+60.15%	32Cr
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	13TCr
REGENERON PHARMACEUTICALS, INC.	+24.67%	12TCr
ARGENX SE	+25.44%	2.77TCr
BIONTECH SE	-17.74%	2.03TCr
GENMAB A/S	-15.17%	1.68TCr
BEIGENE, LTD.	-15.21%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+11.91%	1.48TCr
WUXI APPTEC CO., LTD.	-47.10%	1.46TCr
SAREPTA THERAPEUTICS, INC.	+54.50%	1.44TCr

Bio Therapeutic Drugs